Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 20/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16053107 | 1.00 | QPCT (0.88) | QPCT | |
| SCHEMBL29410567 | 1.00 | QPCT (0.88) | QPCT | |
| SCHEMBL30071568 | 0.94 | QPCT (1.00) | QPCT | |
| SCHEMBL29410459 | 0.90 | QPCT (0.88) | QPCT | |
| SCHEMBL16052619 | 0.90 | QPCT (0.88) | QPCT | |
| SCHEMBL17476423 | 0.90 | QPCT (0.88) | QPCT | |
| SCHEMBL16070928 | 0.87 | QPCT (0.86) | QPCT | |
| SCHEMBL17476412 | 0.87 | QPCT (0.86) | QPCT | |
| SCHEMBL16052732 | 0.86 | QPCT (0.88) | QPCT | |
| SCHEMBL16052735 | 0.86 | QPCT (0.88) | QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658141-B1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPALPHA - CD47 INTERACTION | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2022-11-16 | — | — | EP | claimed |
| EP-2970235-B1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2019-06-19 | — | — | EP | claimed |
| US-9512115-B2 | Inhibitors | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | claimed |
| US-20160031869-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2016-02-04 | — | — | US | claimed |
| EP-2970235-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2016-01-20 | — | — | EP | claimed |
| WO-2014140279-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2014-09-18 | — | — | WO | claimed |
| EP-3658141-B1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPALPHA - CD47 INTERACTION | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2022-11-16 | — | — | EP | disclosed |
| CN-108218849-B | Novel inhibitors | 维沃永治疗公众有限公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-3747438-A1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA - CD47 INTERACTION | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2020-12-09 | — | — | EP | disclosed |
| EP-3747437-A1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA - CD47 INTERACTION | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2020-12-09 | — | — | EP | disclosed |
| EP-2970235-B1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-9512115-B2 | Inhibitors | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20160031869-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031869-A1 | NOVEL INHIBITORS | GLS, GLUL, QPCT | QPCT 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.